Last reviewed · How we verify
MT-3921
At a glance
| Generic name | MT-3921 |
|---|---|
| Also known as | Unasnemab |
| Sponsor | Tanabe Pharma Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury (PHASE2)
- A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM) (PHASE1)
- Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury (PHASE1)
- A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MT-3921 CI brief — competitive landscape report
- MT-3921 updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI